Cinda Bio focuses on lung cancer and other major indications. The first and second lines of non-small cell lung cancer are in clinical phase III, and the second line of EGFR-positive non-small cell lung cancer is in clinical phase III with a combination of Beva monoantigen/chemotherapy regimen. In addition, stomach cancer, esophageal cancer and nasopharyngeal cancer are all in clinical phase III, and new aids of liver cancer are in clinical stage III. Cinda bio-combination program to joint chemotherapy-based, targeted drug combination is less.
Regent's biological differentiation and adequate external cooperation. Junshi biology in liver cancer assistance, liver cancer new auxiliary, urinary tract skin cancer, nasopharyngeal cancer, triple-yin breast cancer on the clinical progress of leading, and other domestic leaders to form differentiated competition. In addition, the company's external cooperation program is more, with Beida Pharmaceutical CM082 jointly used for lung cancer first-line, melanoma, and Zee-Zi biodonafini jointly for liver cancer, with stone pharmaceutical group albumin yewol for breast cancer, with Pfizer Axitini jointly for melanoma, and Hutchison Whampoa Sovantinib jointly for a variety of solid tumors.
Although the progress of domestic new drug research and development is behind the international, but due to the emerging fields or technology start-up differences are not big, there is still the possibility of overtaking the corner. Some head innovation companies have pioneered the me-too into the me-better or fast-follow phase. For example, in the field of immunotherapy, PD-1, CAR-T and other fields, unproven new targets have been domestic enterprises to carry out fast-follow strategic layout.
Zebtinib of Baxter is expected to become the third commercial BTK inhibitor in the world after Ibtiny and acalabrutinib. Ibtini went public at the end of 2013 and has achieved global sales of $6.205 billion in 2018, diastivoly a heavyweight. Zebutinib is the first independently developed cancer drug in China to be recognized by the FDA for breakthrough therapies. Baxter is conducting head-to-head Phase III clinical trials with Ibtini on two indications, most likely as a me-better or even Best-in-class variety.
According to Haitong Securities summary, 2018 is the second wave of domestic innovation drug harvest year. Since 2003, China's first returning scientists to do innovative drug research and development such as Beida, microcore, such as the first batch of local enterprises such as Hengrui also began to invest in innovative research and development, these enterprises after 2011 gradually began to enjoy the results of ten years of investment. After 2014, pharmaceutical reform attracted big wave of scientists, investors, pharmaceutical industry research and innovation began to show signs of blowout, 2018 is the harvest period of this wave of investment.
At the same time, some important participants in China's pharmaceutical industry, such as generics and generics, have been affected by a series of policies, such as volume procurement, product price reduction, control of complementary drugs, and so on, the growth rate has continued to slow. CITIC Jiantou compared the growth rate of different sectors such as biopharmaceuticals and chemicals in recent years, it is clear that there is internal differentiation, the overall growth of the chemical preparations sector slowed down, the growth rate of 2019Q1's homecoming net profit was only 2.9%, and the growth rate of the biopharmaceutical sector was as high as 46.3% due to the outstanding performance of growth hormone and vaccines.
The growth rate of multinational pharmaceutical companies has also started to pick up due to the rapid entry of a large number of heavy varieties into China and the catalysis of medical insurance access, with Q1 growth rates higher in 2018 and 2019 than those of local leading enterprises. Among them, Mercer east due to HPV vaccine and K drug approval in China, in 2018 in China's growth rate of 37%. AstraZeneca's rapid growth of oncology drugs, represented by Oxitinib, has boosted sales in China by 25 per cent, while price cuts and post-health-care releases of Roche's Merova, Hercesterin and Aventin have led to a 23 per cent increase in sales in China. Another trend is that the overall market growth of prescription drugs is higher than the growth rate of public hospital terminals, indicating that the growth rate of retail terminals and primary hospitals is increasing, and the second- and third-tier cities are growing faster than the first-tier city market, and as a result, multinational pharmaceutical companies are accelerating their decline. In 2018, multinational pharmaceutical companies will grow by more than 10% in both second- and third-tier cities, compared with significantly slower growth in local pharmaceutical companies.
In the past year, China's pharmaceutical industry is experiencing a period of class division before the chaos, scientists-led innovation and research and development companies, a large number of imitation pharmaceutical companies, multinational pharmaceutical companies, from imitation to the creation of traditional local pharmaceutical enterprises, Chinese medicine enterprises at the same stage into a period of strategic confusion, by anxiety and trends.
From July 25th to 27th, 2019, EOC Health will host the "GIIS 2019 4th China Great Health Industry Upgrade Summit", which willfocus on the market environment, investment hotspots and industrial change in the four segments of healthcare big data, pharmaceutical innovation, non-public health care and science and technology medical.